Proteostasis Therapeutics Inc Call to Discuss Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients Transcript
Good morning, and welcome, ladies and gentlemen, to the Proteostasis Data Update Conference Call.
At this time, I would like to inform you that this conference call is being recorded.
(Operator Instructions)
At this time, I would like to introduce Claudia Styslinger, Investor Relations. Please go ahead.
Good morning, and thank you for joining us as we report progress in Proteostasis' proprietary combination 28-day Phase II study of posenacaftor, dirocaftor and nesolicaftor.
Joining me this morning are Meenu Chhabra, President and Chief Executive Officer; Dr. Geoff Gilmartin, Chief Medical Officer; and Dr. Marija Zecevic, Chief Commercial Officer. Following prepared remarks today by Meenu, we will open the call for your questions.
During this call, please note that we will be making forward-looking statements. These statements are subject to risks factors and uncertainties, including those that are detailed in today's presentation and our Form 10-K
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |